Review the biological basis of PCSK9, key therapeutic modalities, cardiovascular evidence, and future directions, including insights from the CORALreef clinical program.
Learning Centers
-
Evolution of PCSK9 Inhibitors Modalities: From Monoclonal Antibodies to Oral Macrocyclic Peptides -
Engineering mRNA Therapeutics: Molecular Design, Targeted Delivery, and Translational Challenges Explore advances in mRNA molecular design and targeted delivery, emerging non-LNP platforms, and key translational challenges shaping broader applications beyond vaccines. -
Beyond Aβ Clearance: Exploring Multi-Pathology Strategies in Alzheimer’s Disease Explore how anti-Aβ therapy is reshaping the AD treatment landscape, the rationale for multi-pathology combination strategies, and advances in biomarker-guided precision treatment. -
Beyond Target Competition: Payload Chemistry and the Next Stage of ADC Design Explore the rise of TOP1i-class payloads, the impact of payload–linker design on therapeutic window and developability, and how novel payloads are expanding ADC design boundaries.
